How Much Weight Can You Lose on Semaglutide at Each Dose

Most adults on semaglutide 2.4 mg lose about 15 percent of their body weight over roughly 68 weeks. For a 232 pound starting weight, that lands near 34 pounds. Adults with type 2 diabetes average closer to 10 percent. Your result depends heavily on the dose you reach and how long you hold it.

If you’ve already tried two or three weight loss programs that went nowhere, that number probably reads like marketing. Fair enough. So here is where it comes from, dose by dose, with the trial tables it was pulled out of.

For the wider picture across the whole drug class, our guide on how much weight you can lose on GLP-1 medications covers the comparison. This page stays on semaglutide.

What Do the Semaglutide Trials Actually Show?

Semaglutide was studied in a run of trials called STEP, short for Semaglutide Treatment Effect in People with obesity. The results below sit inside the FDA prescribing information for Wegovy, which is the document your prescriber works from.

Look at the third row for a second. Same semaglutide treatment, same 2.4 mg, and the group wrapped in structured diet and physical activity coaching finished a full percentage point ahead of the standard arm. More than half of them cleared 15 percent. That gap is the part of your weight loss the drug does not do by itself.

The diabetes row matters too. Semaglutide started life as a diabetes drug, so it lowers blood sugar as it lowers weight. Patients with type 2 diabetes still lose real weight, just less on average, and they usually watch A1c drop alongside the scale.

How Much Weight Can You Lose on Semaglutide at Each Dose Step?

Semaglutide dosing climbs in stages. You don’t start at the dose that produced those trial numbers, and that surprises people who expected fast results in month one.

That ladder is straight off the approved label, and it exists to blunt gastrointestinal side effects rather than to slow you down. Roughly four months pass before you reach a maintenance dose. Read the trial average as a 68 week figure, because that’s how it was measured.

Honestly, weeks one through four are where we lose people. Appetite drops, food noise quiets, the scale sits still, and patients decide the semaglutide injection is not working. It’s working. The scale is just the last thing to catch up.

What Changes Once You Reach the Maintenance Dose?

Here’s the stretch few clinics talk about, and it decides your weight loss outcomes.

The FDA label includes a withdrawal study built for exactly this question. Patients climbed to 2.4 mg over a 20 week run-in. Then half continued and half switched to placebo. Between week 20 and week 68, the continuing group lost another 7.9 percent of body weight. The placebo group gained 6.9 percent back.

Two things follow from that. Loss keeps accumulating well past the ramp, so a plateau at month four is not your ceiling. And the medication holds the result only while you take it.

Worth noting who was in that study, though. Only patients who tolerated the climb to 2.4 mg were randomized, so the numbers flatter the drug slightly compared with a general population starting fresh.

Semaglutide vs Tirzepatide: How Far Apart Are the Numbers?

Patients ask this at nearly every consult, usually before they ask about price. Here are the label averages side by side.

Those tirzepatide figures come from the FDA prescribing information for Zepbound. Two separate trial programs, two different patient groups, two different lengths. So the honest reading is that tirzepatide averaged more, not that it will beat semaglutide by six points for you specifically.

Cost, insurance coverage, supply, and how your stomach handles each one all move that decision. We break the tradeoff down on our semaglutide vs tirzepatide page, and the side effect profiles sit on our GLP-1 side effects page.

Why Do Two Patients on the Same Dose Land Far Apart?

Averages hide an enormous spread. In the no-diabetes trial, nearly half the patients cleared 15 percent while others finished in single digits. In our experience the spread in clinic is at least as wide, and it rarely tracks how hard someone is trying. A few things explain the distance.

• Your initial body weight. A heavier starting weight usually means more pounds at the same percentage.
• The dose you actually hold. Reaching and staying at 1.7 mg or 2.4 mg is where the bulk of loss happens.
• Protein and calorie intake. The medication lowers appetite; what you eat inside that quieter window still decides the outcome.
• Physical activity, especially resistance work. Muscle protects your metabolic health while weight comes off.
• Sleep and stress. Short sleep pushes appetite hormones the wrong way.
• Other prescriptions. Some medication for mood, blood sugar, or blood pressure nudges weight upward.
• Type 2 diabetes. It lowers the average, as the table above shows.

One patient of ours held at 1.7 mg for eight months and finished near the trial average. Another needed the full 2.4 mg before much moved at all. Neither did anything wrong, which is why we set weight loss goals from labs and history rather than from a number someone read online.

Is Compounded Semaglutide or the Oral Pill Any Different?

Different, yes. Better studied, no.

Compounded semaglutide is mixed by a pharmacy instead of made by the manufacturer, and it has not been through FDA review for safety, quality, or effectiveness. According to the FDA safety page on semaglutide medications, the agency had received 990 adverse event reports linked to compounded semaglutide as of May 31, 2026. Many involved dosing errors from patients or clinicians measuring doses out of multi-dose vials. The FDA has also flagged salt forms, such as semaglutide sodium, which are not the same active ingredient as the approved drug.

None of that makes a compounded medication automatically wrong for you. It does mean the expected weight loss results from the STEP tables were measured on the branded semaglutide injections, not on a compounded version at an unverified concentration.

Oral semaglutide is a separate question. The semaglutide pill sold as Rybelsus is approved for type 2 diabetes, not as a weight loss medication. Approvals and stock in this category keep shifting, so ask your prescriber what is actually available the week you start.

What Happens to Your Weight If You Stop?

Weight regain is the part patients dread, and it was measured directly.

Researchers followed a subset of the STEP 1 group for a year after treatment ended. That group had lost 17.3 percent by week 68. One year off semaglutide and off the lifestyle program, they had regained 11.6 percentage points, leaving a net loss of 5.6 percent. The published extension in Diabetes, Obesity and Metabolism sums it up plainly: participants regained two thirds of their prior weight loss.

Thankfully, that is biology rather than failure. Appetite returns when the drug leaves. Obesity behaves like a chronic condition, which is why the label reads chronic weight management instead of a twelve week course.

According to the National Institute of Diabetes and Digestive and Kidney Diseases, weight management medication works alongside changes in eating and physical activity, not instead of them. The Mayo Clinic frames these drugs the same way. Losing 5 to 10 percent of your initial body weight already improves blood sugar levels, blood pressure, and cholesterol, so significant weight loss in the clinical sense starts lower than most patients assume.

Our patients almost always ask for the timeline before they ask for the number, and we have learned to answer in that order. The ramp takes about four months before a maintenance dose is even reached, so judging the drug at week six is judging it early.

How We Run Semaglutide Treatment at Foundation Wellness

We start with labs instead of a prescription pad. Your first visit at our American Fork clinic covers blood sugar, thyroid, hormones, and an honest account of what you have already tried.

If semaglutide fits, we map the dose ladder and your weight loss goals together, then book monthly check-ins. Those visits are not ceremonial. The difference between an 8 percent result and a 15 percent result usually comes down to who caught the stall early and adjusted, and to whether protein and resistance training held muscle through the drop.

The question we hear most at that first visit is some version of “will any of this still be gone in two years?” We answer it with the ranges above and with your own labs, not with a promise.

Our patients hear the maintenance conversation at visit one rather than in month nine. A planned taper feels different from an improvised one. Some patients stay on a lower dose long term; others step off with a written plan for food and physical activity.

We serve American Fork, Provo, Lehi, and the rest of Utah, in clinic and by telehealth. You can see how the program runs on our GLP-1 injections in Utah page, real pricing sits on the GLP-1 cost in Utah page, and the wider plan lives on our medical weight optimization page.

This article is general education, not medical advice. Semaglutide is a prescription medication with real risks, and your weight loss journey should be planned with a clinician who has seen your labs.

Key Takeaways

• Adults without diabetes averaged a 14.9 percent drop in body weight on semaglutide 2.4 mg over 68 weeks, near 34 pounds from a 232 pound start.
• Adults with type 2 diabetes averaged 9.6 percent, and adults given intensive lifestyle therapy alongside the drug averaged 16.0 percent.
• The dose climbs every four weeks from 0.25 mg to a 1.7 mg or 2.4 mg maintenance dose around week 17.
• Continuing at 2.4 mg produced another 7.9 percent of loss from week 20 to week 68, while stopping produced a 6.9 percent gain.
• Tirzepatide averaged 20.9 percent at 15 mg in its own separate trials, so a higher dose of a different drug is worth discussing.
• One year after stopping, STEP 1 participants had regained about two thirds of their weight loss.
• Foundation Wellness runs medically supervised weight loss from American Fork, Utah, in clinic and by telehealth.

Sources

• FDA Wegovy prescribing information, semaglutide injection (accessdata.fda.gov).
• FDA Zepbound prescribing information, tirzepatide (accessdata.fda.gov).
• FDA safety page on medications containing semaglutide (fda.gov).
• Wilding and colleagues, STEP 1 trial extension, Diabetes, Obesity and Metabolism, 2022 (pmc.ncbi.nlm.nih.gov).
• NIDDK, prescription medications to treat overweight and obesity (niddk.nih.gov).